Patterns of Symptom Burden During Radiotherapy or Concurrent Chemoradiotherapy for Head and Neck Cancer

被引:100
|
作者
Rosenthal, David I. [1 ]
Mendoza, Tito R. [2 ]
Fuller, Clifton D. [1 ]
Hutcheson, Katherine A. [3 ]
Wang, X. Shelley [2 ]
Hanna, Ehab Y. [3 ]
Lu, Charles [4 ]
Garden, Adam S. [1 ]
Morrison, William H. [1 ]
Cleeland, Charles S. [2 ]
Gunn, G. Brandon [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
symptoms; patient-reported outcomes; radiotherapy; chemoradiotherapy; head and neck cancer; PATIENT-REPORTED OUTCOMES; CHEMORADIATION THERAPY; INVENTORY; ONCOLOGY; MODULE;
D O I
10.1002/cncr.28672
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: A prospective longitudinal study to profile patient-reported symptoms during radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) for head and neck cancer was performed. The goals were to understand the onset and trajectory of specific symptoms and their severity, identify clusters, and facilitate symptom interventions and clinical trial design. METHODS: Participants in this questionnaire-based study received RT or CCRT. They completed the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module before and weekly during treatment. Symptom scores were compared between treatment groups, and hierarchical cluster analysis was used to depict clustering of symptoms at treatment end. Variables believed to predict symptom severity were assessed using a multivariate mixed model. RESULTS: Among the 149 patients studied, the majority (47%) had oropharyngeal tumors, and nearly one-half received CCRT. Overall symptom severity (P < .001) and symptom interference (P < .0001) became progressively more severe and were more severe for those receiving CCRT. On multivariate analysis, baseline Eastern Cooperative Oncology Group performance status (P < .001) and receipt of CCRT (P < .04) correlated with higher symptom severity. Fatigue, drowsiness, lack of appetite, problem with mouth/throat mucus, and problem tasting food were more severe for those receiving CCRT. Both local and systemic symptom clusters were identified. CONCLUSIONS: The findings from this prospective longitudinal study identified a pattern of local and systemic symptoms, symptom clusters, and symptom interference that was temporally distinct and marked by increased magnitude and a shift in individual symptom rank order during the treatment course. These inform clinicians about symptom intervention needs, and are a benchmark for future symptom intervention clinical trials. (C) 2014 American Cancer Society.
引用
收藏
页码:1975 / 1984
页数:10
相关论文
共 50 条
  • [1] Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy
    Xiao, Canhua
    Hanlon, Alexandra
    Zhang, Qiang
    Ang, Kian
    Rosenthal, David I.
    Nguyen-Tan, P. Felix
    Kim, Harold
    Movsas, Benjamin
    Bruner, Deborah Watkins
    [J]. ORAL ONCOLOGY, 2013, 49 (04) : 360 - 366
  • [2] Concurrent chemoradiotherapy for head and neck cancer
    Brockstein, B
    Vokes, EE
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (06) : 786 - 793
  • [3] Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
    Shirasu, Hiromichi
    Yokota, Tomoya
    Hamauchi, Satoshi
    Onozawa, Yusuke
    Ogawa, Hirofumi
    Onoe, Tsuyoshi
    Onitsuka, Tetsuro
    Yurikusa, Takashi
    Mori, Keita
    Yasui, Hirofumi
    [J]. BMC CANCER, 2020, 20 (01)
  • [4] Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
    Hiromichi Shirasu
    Tomoya Yokota
    Satoshi Hamauchi
    Yusuke Onozawa
    Hirofumi Ogawa
    Tsuyoshi Onoe
    Tetsuro Onitsuka
    Takashi Yurikusa
    Keita Mori
    Hirofumi Yasui
    [J]. BMC Cancer, 20
  • [5] Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
    Shirasu, H.
    Yokota, T.
    Fushiki, K.
    Inoue, H.
    Shibata, M.
    Furuta, M.
    Kawakami, T.
    Kawai, S.
    Hamauchi, S.
    Todaka, A.
    Tsushima, T.
    Machida, N.
    Yamazaki, K.
    Fukutomi, A.
    Onozawa, Y.
    Yasui, H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [6] Nutrition Impact Symptom Clusters in Patients With Head and Neck Cancer Receiving Concurrent Chemoradiotherapy
    Wang, Yujie
    Lu, Qian
    Zhang, Lichuan
    Zhuang, Bing
    Zhang, Tong
    Jin, Sanli
    Sun, Yan
    Xiao, Shaowen
    Zheng, Baomin
    Fang, Yu
    Gong, Liqing
    Wang, Yanli
    Cao, Yiwei
    Wang, Weihu
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2021, 62 (02) : 277 - 285
  • [7] Concurrent chemoradiotherapy in head and neck cancer.
    Urba S.G.
    [J]. Current Oncology Reports, 1999, 1 (2) : 105 - 109
  • [8] Symptom Burden during Radiation Therapy and Chemoradiation for Head and Neck Cancer
    Rosenthal, D. I.
    Mendoza, T. R.
    Gunn, G. B.
    Wang, X. S.
    Hanna, E. Y.
    Lu, C.
    Garden, A. S.
    Morrison, W. H.
    Ang, K. K.
    Cleeland, C. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S457 - S457
  • [9] Docetaxel with concurrent radiotherapy in head and neck cancer
    Nabell, L
    Spencer, S
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (06) : 89 - 93
  • [10] Concurrent chemotherapy and radiotherapy for head and neck cancer
    Burri, Ryan J.
    Lee, Nancy Y.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (03) : 293 - 302